Index

A
7AAD, see 7-Amino actinomycin D
AC133 marker, 52
Activation-induced cell death, 21
Acute leukemia, CBT in children with, 197–202
Adipogenic differentiation, of MSCs, 107
Adult cord blood transplantation, 202–205, 211
and bone marrow transplants, 220–221
chimerism analysis, 220
clinical studies in, 213–214
cord blood unit availability, 212
double
myeloablative regimen, 217–218
reduced intensity regimen, 218–219
new applications, 221–222
single
ablative regimens, 214–216
reduced intensity regimen, 216–217
Adult stem cells, 284
AICD, see Activation-induced cell death
7-Amino actinomycin D, 31–32
Anemia
treatment by cord blood in background of advanced rheumatoid arthritis, 246–249
cancer, 252–254
diabetes and microalbuminurea, 240–243
HIV, 251–252
leprosy, 249–251
malaria, 237–240
thalassemia, 256–258
tuberculosis and emaciation, 243–246
umbilical cord blood transfusion for, 292–293
Angiogenesis, 51
Aortic-gonadotropin-mesonephric (AGM) region, 7, 9
Ayyappan, T., 275–287

B
Ballen, K.K., 211–222
Basu, D., 333–356
Basu, H.K., 291–296
Bhattacharya, N., 229–259, 267–273
Bieback, K., 125–144
Bioceramics
bioactive and resorbable
calcium phosphate ceramics, 339–344
glasses and glass-ceramics, 344–348
bioinert, 336–339
as implant materials, 335–336
new-age innovation in, 348–349
BMF syndromes, CBT and, 172–174
Bone marrow transplantation (BMT), 109
Bosch, P., 99–114
Buerger’s disease, 69
Burd, A., 275–287

C
CAFC assays, see Cobblestone area-forming cell assays
Calcium phosphate ceramics, 339–344
Canabarro, R., 27–76
Cancer, cord blood transfusion and, 252–254
CB, see Cord blood
CB-MSC, clinical manufacturing, 137
CBT, see Cord blood transplantation
CD44, on human MSCs, 65
CD90, see Thy-1
CD34+ cells, 29–32, 45–47
CD11c/49e/62L molecule, 38–40
CD117 (c-kit receptor), 34–35
CD33/38/45/61 molecule, 32–34, 39
CD133/164 molecule, 35–36
Central nervous system and spinal injury, MSCs and, 110
Cetrulo, C., 3–14
Cetrulo, K., 3–14
CFU–GMs, see Colony-forming unit–granulocyte macrophages
Chakraborty, J., 333–356
Chakravorty, R.C., 363–369
Chaudhuri, A., 267–273
Chimerism assays, 220
Chondrogenic differentiation, of MSCs, 106–107
Chronic myelogenous leukemia (CML), 203
CMV, see Cytomegalovirus
Cobblestone area-forming cell assays, 20
Colony-forming unit fibroblasts (CFU-F), see Mesenchymal stem cells
Colony-forming unit–granulocyte macrophages, 233
Congenital immune deficiency syndromes, CBT and, 175
Cooleys' anemia, see Thalassaemia
Cord blood, 285
allogeneic and autologous banking
HSC from UCB, advantages and disadvantages, 309–311
progenitors in UCB, factors influencing, 311–312
public and private UCB banking, 314–315
UCB collection, processing, and quality management, 312–314
ex vivo expansion of
of CB-MNC on MSC, 96–97
cells provide rapid engraftment, 94
cellular content, 93–94
clinical grade reagents, availability of, 95
products selection, 94–95
for improving biocompatibility of implants, 321
cell proliferation and differentiation, inductive factors in, 324–326
degenerative diseases and current treatment methodology, 322–323
immune reaction to implant, 326–328
plasticity of, 285–286
of preterm neonates, 49–50
transfusion, see Placental umbilical cord whole blood transfusion
transplantation, see Cord blood transplantation
See also Umbilical cord blood
Cord blood stem cells, 19
amplification, 21–22
and regenerative medicine, 22–23
transplantation biology and immunology, 20–21
Cord blood transplantation
adult, 211
and bone marrow transplants, 220–221
chimerism analysis, 220
clinical studies in, 213–214
cord blood unit availability, 212
double, 217–219
new applications, 221–222
single, 214–217
for hematologic malignancies in adults, 202–205
in children with acute leukemia, 197–202
new strategies, 205–208
for pediatric non-malignant conditions, 163
BMF syndromes, 172–174
Fanconi anemia (FA), 174–175
globoid-cell leukodystrophy, 184–185
hemoglobinopathies, 169–172
Hurler's syndrome, 182–184
inherited metabolic diseases, 180–182
mucopolysaccharidoses, 182
potential disadvantages of, 168–169
primary immune deficiencies, 175–178
reasons for use of, 164–168
Wiskott–Aldrich syndrome (WAS), 178
X-linked ALD, 185–186
Cord Blood Transplantation Study Group (COBLT), 214–215
Cruetzfeldt-Jakob disease, 268–269
CXCR4 (CD184) receptor on HSCs, 36–38
on MSCs, 63
Cyclosporine, 218
Cytomegalovirus, 28, 168
Cord Blood Transplantation Study Group
D
Degenerative disc disease (DDD), 346
Diabetes and microalbuminurea, cord blood transfusion and, 240–243
3,4-Dihydroxyphenylalanine (L-DOPA), 114
Directly Observed Treatment–Short Course (DOTS), 243
E
Embryonic stem cell, 5, 59
like cells, from CB, 142–144
Endosseous ridge maintenance implant, 347
Endothelial progenitor cells, 5
CB-EPC
- isolation, expansion, and in vitro characterization of, 138–139
- therapeutic potential, 140–142
HUVECs, 11–13
- from UCB, 50–51
  - clinical importance, 56–58
  - culture, 55–56
- surface molecules expressed in, 52–54
EPCs, see Endothelial progenitor cells
Epstein Barr Virus, 28
ERMI, see Endosseous ridge maintenance implant
ESCs, see Embryonic stem cell
Ex vivo expansion, of CB of CB-MNC on MSC, 96–97
- cells provide rapid engraftment, 94
- cellular content, 93–94
- clinical grade reagents, availability of, 95
- products selection, 94–95

F
Fanconi’s anemia (FA), 3, 9, 269
- CBT and, 174–175
Fetal bovine serum (FBS), 128
Fetal hemoglobin, 231
Fetal wound healing, 279
Fibroblast growth factor 2 (FGF-2), 102
Fibronectin receptor (CD29), 65
Flt3 receptor (CD135), 36

G
Gene therapy
- mesenchymal stromal cells and, 136–137
  - with MSCs, 71–72, 111–114
Globoid-cell leukodystrophy, CBT and, 184–185
Glomerular filtration rate (GFR), 241
Graft versus host disease (GVHD), 28, 47–48
- CBT and, 167–168
- MSCs and, 70
Granulocyte-macrophage colony-stimulating factor (GM-CSF), 42

H
Healing (regeneration and repair), 277–280
Hemangioblasts, 50
Hematopoietic growth factors, 94
Hematopoietic stem cells, 3, 9–10, 28
- surface molecules expressed in stem and progenitor cells from UCB
  - CD33/34/38/45, 29–34
  - CD117/133/164, 34–36
  - CD184 (CXCR4), 36–38
CD135 (Flt3 receptor), 36
CD90 (Thy-1), 34
- transplantations (HSCT), 163
from UCB
- advantages and disadvantages, 309–311
- clinical importance, 47–48
- cord blood of preterm neonates, 49–50
- culture, 41–44
- markers and adhesion molecules expressed in, 38–41
- physiological, hematological, and immunophenotypical correlations, 44–47
Hemoglobinopathies, CBT and
- sickle cell disease, 171–172
- thalassaemia, 169–171
HGFs, see Hematopoietic growth factors
Hollands, P., 19–23
Holzgreve, W., 309–315
HSCs, see Hematopoietic stem cells
Huang, L., 275–287
Human Fertilisation and Embryology Act of 1990, 301
Human immunodeficiency virus (HIV), cord blood transfusion and, 251–252
Human leukocyte antigen (HLA)-DR, 28, 40–41
Human umbilical vein endothelial cells (HUVECs), 11–13, 138
Huntington’s disease, 268
Hurler’s syndrome, CBT and, 182–184

I
Inborn metabolic diseases, CBT and, 180–182
Insulin-like growth factor 1 (IGF-1), 103
Interferon-γ (INF–γ), 241
International Society of Hematotherapy and Graft Engineering (ISHAGE) protocol, 31–32

J
“Jell cells” (JCs), 9

K
Kaladhar, K., 321–328
Kilo, T., 163–189
Kinase insert domain receptor (KDR), 54
KLF2 factor, 12
Kluter, H., 125–144
Krabbe’s disease, see Globoid-cell leukodystrophy
L
Langerhans cell histiocytosis (LCH), 186
Leprosy, cord blood transfusion and, 249–251
Long-term culture-initiating cells (LTCIC), 22

M
Macrophage-CSF (M-CSF), 42
Malaria, cord blood transfusion and, 237–240
MAP-2, see Microtubule-associated protein 2
MAPCs, see Multipotent adult progenitor cells
Marrow isolated adult multilineage inducible cells, 74–75
McNiece, I.K., 93–98
Mehta, A., 3–14
Mesenchymal stem cells, 3–5, 10–11, 99
differentiation potential of
adipogenic, 107
chondrogenic, 106–107
osteogenic, 105–106
isolation and culture of, 100–104
phenotypic characterization of, 104–105
therapeutic applications, 107
central nervous system and spinal injury, 110
gene therapy, genetically modified MSCs for, 111–114
local transplantation, 108–109
myocardial repair, 110
systemic transplantation, 109–110
from UCB, 58–61
CD29, CD44, CD90 and Stro-1 molecule, 65
clinical importance, 67–72
culture, 66–67
CXCR4, 63
differentiation, 62
Mesenchymal stromal cells (MSCs), 127
isolation, expansion and in vitro characterization, 129–132
therapeutic potential
CB-MSC, clinical manufacturing of, 137
gene therapy, 136–137
hematopoietic support, 134–135
immune modulation, 135–136
regenerative medicine, 133–134
Methotrexate (MTX), 170–171
MIAMICs, see Marrow isolated adult multilineage inducible cells
Microtubule-associated protein 2, 127
MMF, see Mycophenolate mofetil
MSCs, see Mesenchymal stem cells

Mucopolysaccharidoses, CBT and, 182
Multipotent adult progenitor cells, 74, 104, 142
Mycophenolate mofetil, 218
Mycobacterium leprae, 249–250
Myocardial repair, MSCs and, 110

N
National Institute for Biological Standards and Control, 301
National Marrow Donor Program, 212
Neural stem cells, 5
Neurology, umbilical cord blood therapy and brain diseases, 270–272
CRT and, 267–268
potential risks of, 272
scope of, 269–270
NIBSC, see National Institute for Biological Standards and Control
NMDP, see National Marrow Donor Program
Non-hematopoietic stem and progenitor cells, from UCB, 125
CB-EPC, 137
isolation, expansion, and in vitro characterization, 138–139
therapeutic potential, 140–142
embryonic stem cell-like cells, 142–144
mesenchymal stromal cells (MSCs), 127
isolation, expansion and in vitro characterization, 129–132
therapeutic potential, 133–137
Non-obese diabetic/severe combined immunodeficiency (NOD/SCID) repopulation assay, 20, 41
NSCs, see Neural stem cells

O
Orthopedic implants, stem cell potential in, 333
bioceramics
bioactive and resorbable, 339–348
bioinert, 336–339
as implant materials, 335–336
new-age innovation in, 348–349
tissue engineering, 349–355
Osteogenesis imperfecta (OI), 133
Osteogenic differentiation, of MSCs, 105–106

P
PAR-1, see Proteinase-activated receptor-1
Parkinson’s disease, 68, 268
PDGF, see Platelet-derived growth factor
Peripheral blood mononuclear cells (PB-MNCs), 12–13
Peripheral blood progenitor cell (PBPC), 93
PGCs, see Primordial germ cells
Placental and pregnancy stem cells
  endothelial progenitor cells, see Endothelial progenitor cells
  fetal cells in maternal circulation, 13–14
HSCs, see Hematopoietic stem cells
MSCs, see Mesenchymal stem cells
  ontogeny of, 8–9
  placenta/amnion, amniotic fluid, and umbilical cord, embryology of, 5–8
plasticity, 5
Placental umbilical cord whole blood transfusion, 229
disease, age, and sex distribution of patients, 236–237
effect and prognostic implications of treatment with, 254–256
material and methods, 234–236
other blood substitutes and, 230–233
pre-clinical and clinical studies, 233–234
in treatment of anemia in background of advanced rheumatoid arthritis, 246–249
cancer, 252–254
diabetes and microalbuminurea, 240–243
HIV, 251–252
leprosy, 249–251
malaria, 237–240
thalassemia, 256–258
tuberculosis and emaciation, 243–246
Plasmodium falciparum, 237
Platelet-derived growth factor, 102–103
Platelet endothelial cell adhesion molecule-1 (PECAM-1), 39
Pranke, P., 27–76
Primordial germ cells, 8–9
ProCOUNT™ (BD) method, 31
Proteinase-activated receptor-1, 54
P-selectin glycoprotein ligand 1 (PSGL-1), 140
Q
Quillen, K., 197–209
R
Regenerative medicine
  cord blood stem cells and, 22–23
  mesenchymal stromal cells and, 133–134
Rheumatoid arthritis (RA), cord blood transfusion and, 246–249
SDF-1, see Stromal-derived factor
Sharma, C.P., 321–328
Shaw, P.J., 163–189
Shpall, E.J., 93–98
Sickle cell disease (SCD), 171–172
Simian virus 40 large T antigen, 141
Skin
  healing (regeneration and repair), 277–278
  fetal wound, 279
  need for skin substitutes, 280
  structure and function, 276–277
  tissue engineering, strategy of, 280–283
Stacey, G.N., 301–308
Stem cells, 283
  adult, 284
  cord blood, see Cord blood
  epilogue, 368–369
  ethics, 363–364
  modern medical ethics, 364–365
  potential, in orthopedic implants, 333
    bioactive and resorbable ceramics, 339–348
    bioceramic implants, 335–336, 348–349
    bioinert ceramics, 336–339
    tissue engineering, 349–355
  research, 364–368
  wound healing modulation, 286–287
  See also Specific types
Stice, S.L., 99–114
Stromal-derived factor, 36–37
Stro-1 molecule, 65
Stubblefield, P., 3–14
SV40T antigen, see Simian virus 40 large T antigen
T
T-cell-depleted unrelated bone marrow transplants, 199
TCSCs, see Tissue committed stem cells
Ternary SiO2-Na2O-CaO diagram, 344
TGF-β, see Transforming growth factor beta
Thalassaemia, 169–171
cord blood transfusion and, 256–258
Thy-1, 34, 65
Tie-1/2, 53
Tissue committed stem cells, 75
Tissue engineering
  orthopedic, 349–355
  skin, strategy of, 280–283
Transforming growth factor beta, 103
Transfusion-transmissible diseases (TTDs), 229–230
Troeger, C., 309–315
Tuberculosis and emaciation, cord blood transfusion and, 243–246
T-UBMT, see T-cell-depleted unrelated bone marrow transplants
Tumor necrosis factor-α (TNF-α), 241

U
UCB, see Umbilical cord blood
UK stem cell bank (UKSCB), 301
aims and remit for, 302
cell banking, definition and principle, 304
cell lines
for clinical use, 306
fundamental characteristics, 305
cells donation to, 303
embryonic stem cells in vitro, 305–306
key operational principles for, 302
NIBSC interactions with stem cell community, 307
progress in establishment of, 306–307
Umbilical cord blood
banking
collection, processing, and quality management, 312–314
HSC from UCB, advantages and disadvantages of, 309–311
progenitors in UCB, factors influencing, 311–312
public and private, 314–315
therapy, in neurology
brain diseases, 270–272
CRT and, 267–268
potential risks of, 272
scope of, 269–270
transfusion, 291, 293–294
for anemia, 292–293
blood banking issues, 295
collection and storage, 294–295
elderly patients, 293
indications for, 292
potential hazards, 295
Umbilical cord blood (UCB) stem cells (SCs), 27
EPCs, 50–51
clinical importance, 56–58
culture, 55–56
surface molecules expressed in, 52–54
HSCs
clinical importance, 47–48
cord blood of preterm neonates, 49–50
culture, 41–44
markers and adhesion molecules expressed in, 38–41
physiological, hematological, and immunophenotypical correlations, 44–47
MAPCs, 74
MIAMICs, 74–75
MSCs, 58–61
CD29, CD44, CD90 and Stro-1 molecule, 65
clinical importance, 67–72
culture, 66–67
CXCR4, 63
differentiation, 62
surface molecules expressed in HSCs
CD33/34/38/45, 29–34
CD117/133/164, 34–36
CD184 (CXCR4), 36–38
CD135 (Flt3 receptor), 36
CD90 (Thy-1), 34
TCSCs, 75
USSCs, 72–74
Unrestricted somatic stem cells (USSCs), 72–74

V
Vascular endothelial growth-factor receptor (VEGFR), 53–54
Von Kossa silver reduction method, 105–106
Von Willebrand factor, 12

W
Wharton’s jelly, 7
Wiskott–Aldrich syndrome (WAS), CBT and, 178

X
X-linked adrenoleukodystrophy (ALD), CBT and, 185–186